INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(107,254,126) | $(135,117,352) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,752,147 | 2,621,649 |
| Amortization of intangible assets | — | 145,417 |
| Amortization of operating lease right-of-use assets | 1,377,895 | 736,472 |
| Change in fair value of common stock warrant liability | (2,808,608) | — |
| Impairment of goodwill | — | 10,513,371 |
| Impairment of intangible assets | — | 1,984,444 |
| Deferred taxes | — | (32,046) |
| Non-cash stock-based compensation | 6,595,108 | 11,072,486 |
| Non-cash interest on senior convertible notes | (355,654) | 155,814 |
| Amortization of discounts on investments | (1,690,527) | (4,686,144) |
| Realized loss on sales of short-term investments | 1,905,369 | 4,805,804 |
| Net (gain) loss on disposal of fixed assets | (22,466) | 317,997 |
| Loss (gain) on equity investment in affiliated entity | 1,166,443 | (773,145) |
| Net unrealized gain on available-for-sale equity securities | (2,077,182) | (5,850,626) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, including from affiliated entities | 1,206,172 | 9,332,988 |
| Prepaid expenses and other current assets, including from affiliated entities | 1,483,393 | 39,020,611 |
| Other assets | 38,900 | 78,729 |
| Accounts payable and accrued expenses, including due to affiliated entities | (3,367,087) | (45,989,061) |
| Accrued clinical trial expenses | (343,522) | (8,228,691) |
| Operating lease right-of-use assets and liabilities, net | (1,573,401) | (2,020,971) |
| Grant funding liability, including from affiliated entity | (109,407) | (2,453,297) |
| Net cash used in operating activities | (104,076,553) | (124,365,551) |
| Cash flows from investing activities: | ||
| Purchases of investments | (54,138,026) | (203,475,052) |
| Proceeds from sale or maturity of investments | 158,637,578 | 284,932,562 |
| Purchases of capital assets | (487,832) | (320,898) |
| Proceeds from sale of capital assets | 59,319 | 6,219,263 |
| Net cash provided by investing activities | 104,071,039 | 87,355,875 |
| Cash flows from financing activities: | ||
| Repayment of convertible senior notes | (16,415,000) | — |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 16,146,397 | — |
| Proceeds from issuance of common stock, net of issuance costs | 36,033,473 | 5,461,745 |
| Proceeds from issuance of warrants | 16,063,796 | — |
| Proceeds from stock option exercises | 67,675 | — |
| Taxes paid related to net share settlement of equity awards | (420,795) | (466,646) |
| Net cash provided by financing activities | 51,475,546 | 4,995,099 |
| Effect of exchange rate changes on cash and cash equivalents | 32,403 | (3,920) |
| Increase (decrease) in cash and cash equivalents | 51,502,435 | (32,018,497) |
| Cash and cash equivalents, beginning of period | 14,310,862 | 46,329,359 |
| Cash and cash equivalents, end of period | $65,813,297 | $14,310,862 |
| Supplemental disclosure: | ||
| Interest paid | $533,487 | $1,066,975 |
| Issuance of common stock as part of litigation settlement | $— | $14,000,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.